GlassScriptPhysician profile
Darwin Luke Roman
NPI 1821478082
$8,638.09
in general payments reported to CMS, 2019-2025
31 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $1,402 · 2021: $3,172 · 2022: $2,206 · 2024: $24.69 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $43.25 · Food and Beverage: $24.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $43.25 |
| Food and Beverage | $24.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,015.79 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $905.48 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $866.03 | 2019-2025 | Enhertu |
| Genzyme Corporation | $676.55 | 2021-2022 | |
| Amgen INC. | $668.54 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $663.33 | 2019-2022 | |
| Incyte Corporation | $649.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $420.42 | 2019-2022 | |
| Seagen INC. | $397.09 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $376.07 | 2022 | |
| Lilly USA, LLC | $315.29 | 2021 | |
| Astellas Pharma US INC | $249.39 | 2019 | |
| Janssen Biotech, INC. | $219.76 | 2021-2022 | |
| Exelixis INC. | $211.19 | 2019-2021 | |
| Epizyme, INC. | $125.00 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $121.14 | 2021 | |
| Akcea Therapeutics, INC. | $118.80 | 2019 | |
| Agios Pharmaceuticals, INC. | $113.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.62 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.27 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $70.74 | 2020 | |
| Servier Pharmaceuticals LLC | $63.64 | 2022 | |
| Abbvie INC. | $46.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.05 | 2022 | |
| Blueprint Medicines Corporation | $30.08 | 2020 | |
| Daiichi Sankyo INC. | $24.87 | 2022 | |
| Glaxosmithkline, LLC. | $24.69 | 2024 | Jemperli, Zejula |
| Emmaus Medical, INC. | $18.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.45 | 2020 | |
| Eisai INC. | $16.75 | 2022 | |
| Pfizer INC. | $16.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darwin Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.